Solid Tumours Harboring NRG1 Fusion research hub

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

This study is looking at a new drug called zenocutuzumab for people with certain solid cancers that have a specific genetic change (called an NRG1 fusion). It aims to see if the drug is safe, how well it's tolerated, and if it can help shrink the cancer.